GLP-1 (glucagon-like peptide-1) is a potent insulin secretagogue released from L cells in the intestine. The regulation of GLP-1 secretion has been described both in vivo and in vitro in several animal species, but data from human cellular models are lacking. For this purpose, factors and cell-signaling pathways regulating GLP-1 secretion were investigated in the NCI-H716 human intestinal cell line. After differentiation, these cells homogeneously produced 16.8 pmol GLP-1/mg protein with a basal release of 4.2% during a 2-h incubation period. Nutrients, such as palmitic acid, oleic acid, and meat hydrolysate, stimulated GLP-1 secretion in a dose-dependent manner, as did the cholinergic agonist carbachol and the neu- the distal ileum and colon, is posttranslationally processed into GLP-1 (glucagon-like peptide-1), a potent insulin secretagogue (1). In addition to potentiating glucose-induced insulin secretion, GLP-1 stimulates proinsulin gene expression and biosynthesis (2). Furthermore, GLP-1 has been recently shown to promote satiety and reduce food intake through interactions with the hypothalamus (3, 4).
P ROGLUCAGON, SYNTHESIZED BY L cells found in
the distal ileum and colon, is posttranslationally processed into GLP-1 (glucagon-like peptide-1), a potent insulin secretagogue (1) . In addition to potentiating glucose-induced insulin secretion, GLP-1 stimulates proinsulin gene expression and biosynthesis (2) . Furthermore, GLP-1 has been recently shown to promote satiety and reduce food intake through interactions with the hypothalamus (3, 4) .
Increasing insulin secretion is a key goal in the treatment of type 2 diabetes. Stimulation of the endogenous release of GLP-1 is an attractive alternative to parenteral administration of the peptide. For this purpose, a number of cellular models of animal origin have been used to study the regulation of GLP-1 secretion, such as isolated canine L cells (5) , fetal rat intestinal cell cultures (6) , and the murine enteroendocrine cell lines STC-1 (7) and GLUTag (8) . These cellular models have provided useful information regarding the signaling pathways that regulate proglucagon gene expression and GLP-1 secretion. The activation of PKA was reported to induce both proglucagon gene expression and GLP-1 secretion, whereas PKC activation increased only GLP-1 secretion (2, 5, 8) . These animal cellular models do not necessarily exhibit the same intracellular regulating mechanisms that are active in human L cells. Indeed, glucose-dependent insulinotropic polypeptide, a potent stimulator of GLP-1 secretion in rodent models, is ineffective on human L cells in vivo (8 -10) . Mixed meals as well as oral administration of carbohydrates, lipids, and amino acids have been shown to stimulate GLP-1 secretion in humans (11) (12) (13) . The mechanisms through which such regulation occurs in humans have been poorly characterized, probably because of the difficulty in isolating a truly homogeneous L cell population. The NCI-H716 cell line, derived from a poorly differentiated adenocarcinoma of human cecum (14) , has been described to display some endocrine features, in particular the formation of secretory granules and chromogranin A expression (15) . Furthermore, this cell line expresses several neurohormonal receptors, including receptors for gastrin, serotonin, and somatostatin (16) . The purpose of this study was to evaluate whether the NCI-H716 cell line represents a valuable human cellular model for studying the regulation of GLP-1 expression and secretion.
Materials and Methods Materials
RPMI 1640 medium, DMEM, l-glutamine, penicillin, streptomycin, and FBS were from Life Technologies, Inc. (Basel, Switzerland). BSA was purchased from Serological Proteins, Inc. (Kankakee, IL). Forskolin, ionomycin, 3-isobutyl-1-methylxanthine (IBMX), and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma (Buchs, Switzerland) and dissolved in dimethyl sulfoxide (DMSO) (Socochim, Lausanne, Switzerland). Meat hydrolysate (MH) was purchased from Sigma and prepared as an 8% (wt/vol) stock solution in Krebs-Ringer bicarbonate buffer (KRB) containing 0.2% BSA (wt/vol). The pH was adjusted to 7.2 with NaOH. The solution was filtered through 0.2-m filters, and aliquots were stored at Ϫ20 C. Oleic and palmitic acids (sodium salt) were obtained from Sigma. They were prepared as 8 mm stock solutions in KRB containing 10% BSA (fraction V, fatty acid free; Sigma) and incubated overnight at 37 C on a rotating wheel to allow equilibration of the fatty acid with the BSA. Carbachol was purchased from Sigma and dissolved in H 2 O. Fura-2/AM and Pluronic F-127 were obtained from 
Cell line and culture conditions
Human NCI-H716 cells were obtained from the American Type Culture Collection (Manassas, VA). The NCI-H716 cell line was initiated from ascites fluid of a 33-yr-old Caucasian male with poorly differentiated adenocarcinoma of the colon (14) . This is a hypotriploid human cell line with a modal chromosome number of 61 occurring in 28% of cells. Commonly occurring colorectal tumor markers such as CA 19-9, TAG-72, and CEA were not expressed by these cells (14) . For proliferation maintenance, the cells were grown in suspension in RPMI 1640 supplemented with 10% FBS, 2 mm l-glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin. Cell adhesion and endocrine differentiation were initiated by growing cells in dishes coated with Matrigel (Becton Dickinson and Co., Bedford, MA) in high-glucose DMEM, 10% FBS, 2 mm l-glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin as described previously (15) .
Secretion studies
Two days before the experiments, 1 ϫ 10 6 cells were seeded in 12-well culture plates coated with Matrigel. On the day of the experiment, supernatants were replaced by KRB containing 0.2% (wt/vol) BSA with or without test agents. The solutions were adjusted to pH 7.2. Cells were incubated for 2 h at 37 C with the different effectors or with DMSO or BSA (when fatty acids were used as effectors) alone as a control. The 2-h cell incubation with the different effectors did not affect cell viability (data not shown). Supernatants were collected with the addition of 50 g/ml phenylmethylsulfonyl fluoride and frozen at Ϫ80 C for subsequent analysis. Cells were scraped off and sonicated in a homogenization buffer [1 n HCl containing 5% (vol/vol) HCOOH, 1% (vol/vol) trifluoroacetic acid, and 1% (wt/vol) NaCl]. To normalize GLP-1 content, cell homogenate proteins were measured using the Bio-Rad Laboratories, Inc. (Munich, Germany) protein assay. Peptides were extracted from the cell media and homogenates using an alcohol extraction method as described by the supplier of the GLP-1 (7-36) Total RIA Kit (Linco Research, Inc., St. Charles, MO). This kit, used to determine concentrations of GLP-1, measures GLP-1 and GLP-1 (9-36) with less than 0.4% cross-reactivity with GLP-1 (7-37). The ED 50 of the assay was 72 pm. The intraassay coefficient of variance was 2.3%. Biologically active GLP-1 (7-36) was measured as described by the supplier of the GLP-1 (Active) RIA Kit (Linco Research, Inc.). This kit reacts less than 0.1% with GLP-1 (9-36).
RNA isolation and RT-PCR
A total of 2 ϫ 10 6 cells were seeded in six-well culture plates coated with Matrigel and grown as described above. After 24 h, fresh medium without serum but containing 0.2% BSA and the test agents were added. After 18 h, cells were washed with HBSS and stored at Ϫ80 C until RNA extraction using the RNeasy Total RNA Purification System (QIAGEN AG, Basel, Switzerland).
RT was performed with an input of 1 g of total RNA using the first strand cDNA synthesis kit for RT-PCR (avian myeloblastosis virus; Roche Biomedical, Basel, Switzerland) with oligo d(T) 15 as primer. Primers used for the amplification of cDNAs of interest were synthesized by Mycrosynth (Windisch, Switzerland). The sequences of the forward and reverse primers were (respectively): 5Ј-GTA-ATGCTGGTACAAGGCAG-3Ј and 5Ј-TTATAAAGTCCCTGGCG-GCA-3Ј for the proglucagon gene, 5Ј-TATCGCAGAGAACGGAT-GGC-3Ј and 5Ј-TTGGAAACGCCAAGC-3Ј for the cholecystokinin gene, 5Ј-GCTGACTGATACACTCCAAG-3Ј and 5Ј-TCCCAGTCT-GCTGCATAGAA-3Ј for the c-fos gene, 5Ј-CCACCCATGGCAAAT-TCCATGGCA-3Ј and 5Ј-TCTAGACGGCAGGTCAGGTCCACC-3Ј for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, and 5Ј-GTTGCTATCCAGGCTGTG-3Ј and 5Ј-CATAGTCCGCCTA-GAAGC-3Ј for the actin gene. PCR involved heating for two cycles to 98 C for 1 min, 60 C for 2 min, and 72 C for 2 min and then cycling 28 times through a 1-min denaturation step at 94 C, a 1-min annealing step at 60 C, and a 2-min extension step at 72 C in a DNA thermal cycler apparatus (Bioconcept, Allschwil, Switzerland). The 30 cycles used for the detection of the proglucagon transcripts correspond to the linear portion of the amplification curve (data not shown). GAPDH or actin primers were included in the reaction as internal controls. PCR products (10 l) were separated on a 2% agarose gel and visualized by ethidium bromide staining. Quantification of the PCR products was performed using the densitometric NIH Imager Program.
Northern blotting
Northern blotting was performed as previously described (17) with minor modifications. Actin was used as the control gene to correct for any total RNA loading differences. A 472-bp PCR-generated fragment of the proglucagon gene and a 739-bp PCR-generated fragment of the actin gene were labeled by nick translation with ␣-32 P (Amersham Pharmacia Biotech, Little Chalfont, UK). A single proglucagon transcript of 1.6 kb and a single ␤-actin transcript of 1.8 kb were detected.
Immunofluorescence
Cells were plated in four-well glass chamber slides at 0.2 ϫ 10 6 cells/well and incubated for 2 days at 37 C. Immunofluorescence was then performed as previously described (18), except that cells were incubated overnight at 4 C with the rabbit antihuman GLP-1 antibody diluted 1:100 (Affiniti Research Products Ltd., Exeter, UK), which, according to the supplier, reacts with the mid-to C-terminal domain of GLP-1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and recognizes GLP-1 (1-37), (1-36amide), and (7-36amide).
Cytosolic calcium measurement
Cytosolic free calcium concentration ([Ca 2ϩ ] c ) was measured by Fura-2 fluorescence. NCI-H716 cells grown on Matrigel-coated glass coverslips were washed three times with PSS buffer and incubated in the dark for 45 min at room temperature with Fura-2/AM (5 m) in PSS buffer containing 0.01% Pluronic F-127. Cells were washed six times with PSS, and the coverslip was analyzed in a thermo-regulated chamber (37 C) on a Nikon (Tokyo, Japan) Diaphot inverted epifluorescence microscope with a PhoCal cell fluorescence analyzer (Life Science Resources, Cambridge, UK). The cells were illuminated with alternating light of 340 and 380 nm from a rotating filter wheel (6.25 hertz). Emission was monitored at 510 nm, and data were analyzed using the PhoCal software. Calibrations were performed by treating the cells with CaCl 2 (6 mm) and ionomycin (10 m) to obtain the maximal signal, followed by the addition of EGTA (20 mm) to obtain the minimal signal. Background fluorescence, obtained by quenching the Ca 2ϩ signal with MnCl 2 (10 mm), was subtracted from the signals. Results are given as fluorescence intensity ratio (340:380 nm) and as [Ca 2ϩ ] c calculated as described (19) .
Calculations and statistics
Data in the figures are presented as means Ϯ sem and represents at least three experiments measured in duplicate. Differences between treatments were determined using the one-way ANOVA model. Statistical significance is defined as P Յ 0.05.
Results

NCI-H716 cells secrete high levels of GLP-1
The human intestinal NCI-H716 cell line was described to differentiate into endocrine cells, but its capacity to secrete incretins has not been evaluated (15) . For this reason, both cellular and secreted GLP-1 levels were determined in NCI-H716 cells cultivated on a Matrigel matrix for 2 d in the presence of 10% FBS. These conditions have been described previously as the best differentiation conditions for these cells (15) . The total content of GLP-1 in NCI-H716 cells, as monitored by RIA measuring both GLP-1 (7-36) and (9-36), was 16.8 Ϯ 3.4 pmol/mg protein. Basal release during a 2-h incubation period was 4.2 Ϯ 0.9% of total cell content (n ϭ 16). The biologically active GLP-1 (7-36)NH 2 secreted by NCI-H716 cells represented 62 Ϯ 4% (n ϭ 6) of the total secreted GLP-1 (7-36 and 9-36 forms), as determined by RIA specific for the active form. The homogeneity of the cellular population to produce GLP-1 was monitored by immunochemistry using antiserum specific for both active and inactive forms of GLP-1, as described in Materials and Methods. Fig. 1 shows that GLP-1 staining was uniformly distributed in all cells. At a higher magnification (ϫ400), the immunofluorescent staining was visible as discrete dots scattered in the cytoplasm, indicating that intracellular GLP-1 storage was restricted to secretory vesicles (data not shown).
Fatty acids and MH stimulate GLP-1 secretion in NCI-H716 cells
Among nutrients, fatty acids and protein hydrolysates have been shown to stimulate GLP-1 secretion in rodent cellular models (8, 20) . To determine whether human cells react in a similar way, the amount of GLP-1 released by NCI-H716 cells treated for 2 h with increasing concentrations of palmitic acid, oleic acid, or MH was measured. As shown in Fig. 2A , both palmitic and oleic acid stimulated GLP-1 secretion, with a maximal effect at 0.8 mm (1.8 Ϯ 0.2-fold and 1.6 Ϯ 0.1-fold increase, respectively, compared with the control value). MH also induced a concentration-dependent increase in GLP-1 release, with a plateau at 1% MH corresponding to a 5.0 Ϯ 0.9-fold stimulation (Fig. 2B) .
The neuromediator gastrin-releasing peptide (GRP) and the cholinergic agonist carbachol increase GLP-1 secretion in NCI-H716 cells
Another important pathway for the regulation of GLP-1 secretion is the neuronal axis. It has been shown that the vagal nerve mediates the early response of L cells to nutrients in rats (21) . Among the different neuromediators previously tested for their capacity to stimulate GLP-1 release, carbachol, a cholinergic agonist, and GRP were shown to stimulate GLP-1 release in cellular and organ models (7, 8, 22) . NCI-H716 cells incubated during 2 h with increasing concentrations of carbachol showed a dose-dependent increase in GLP-1 release, with a maximum of 1.5 Ϯ 0.2-fold at the maximal dose tested (1 mm; Fig. 3A ). GRP at 0.7 m increased 2.2 Ϯ 0.2-fold GLP-1 secretion, whereas GRP at 0.07 m did not show significant effects (Fig. 3A) .
PKA and PKC activators stimulate GLP-1 secretion in NCI-H716 cells
The PKC and PKA signaling pathways were reported to be involved in the stimulation of GLP-1 secretion in rodent intestinal cell cultures (23) and in canine L cells (5). To determine whether these signaling pathways were able to regulate GLP-1 secretion in human cells, the effects of the PKA and PKC activators forskolin and PMA were investigated in the NCI-H716 cell line. As shown in Fig. 3B, forskolin (50 m) 
FIG. 1. Immunofluorescent staining of NCI-H716 cells with anti-
GLP-1 antibody. Cells were plated on glass chamber slides, incubated for 2 d at 37 C to allow differentiation, and immunostained for GLP-1 protein. Magnification: ϫ200. The negative control (secondary antibody alone) did not exhibit any fluorescence (data not shown).
FIG. 2. Effects of fatty acids (A) and MH (B) on GLP-1 secretion by
NCI-H716 cells. Cells were incubated for 2 h with increasing concentrations of oleic acid (F) and palmitic acid (f) (for both fatty acids, the fatty acid-to-BSA ratio was 5:1) (A) and MH (F) (B). Secretion into the medium is normalized to the total cellular content and expressed as a percentage of the control value. Results represent means Ϯ SEM of three experiments. *, P Յ 0.05; **, P Յ 0.01).
and PMA (1 m) induced 1.7 Ϯ 0.2-fold and 4.3 Ϯ 0.6-fold increases of GLP-1 secretion, respectively. Simultaneous activation of both PKA-and PKC-dependent pathways with 50 m forskolin and 1 m PMA resulted in a 4.6 Ϯ 0.8-fold increase (Fig. 3B) .
Calcium participates in the mechanism of GLP-1 secretion in NCI-H716 cells
To investigate whether cytosolic calcium is involved in GLP-1 secretion in NCI-H716 cells, the amount of GLP-1 released in the medium of cells treated with the calcium ionophore ionomycin was measured. As shown in Fig. 3B , a 2-h ionomycin treatment induced a concentration-dependent increase in GLP-1 secretion, with a plateau at 2 m corresponding to a 4.5 Ϯ 0.2-fold stimulation. As expected, ionomycin was also able to increase [Ca 2ϩ ] c in NCI-H716 cells (Fig. 4A ). Both ionomycin-induced GLP-1 secretion and [Ca 2ϩ ] c were completely abolished when cells were incubated with EGTA ( Fig. 4A and data not shown) . Interestingly, the addition of 0.7 m GRP on NCI-H716 cells led to an immediate increase in [Ca 2ϩ ] c , followed by a sustained plateau (Fig. 4B) .
Activators of GLP-1 secretion do not modulate glucagon gene expression in NCI-H716 cells
In addition to their effects on the release of GLP-1, PKA activators as well as protein hydrolysates have been shown to up-regulate proglucagon gene expression in rodent cell lines (8, 20) . In NCI-H716 cells, no change in proglucagon mRNA was observed when cells were incubated for 18 h with forskolin/IBMX (10 m each), PMA (1 m), ionomycin (2 m), or increasing concentrations of MH (0.5-2%; Fig. 5 ). These results obtained by RT-PCR (Fig. 5A) were confirmed by Northern blot analysis (Fig. 5B) . Using this technique, no change in proglucagon mRNA was detected except a small yet significant decrease after 18 h of incubation with forskolin/IBMX and 2% MH. A time course performed at 6, 12, 18, 24, and 48 h confirmed that no change occurred in the levels of proglucagon mRNA with the same test compounds (data not shown). On the contrary, the expression of the early response gene c-fos was 1.8-or 2.6-fold induced when forskolin/IBMX (10 m each) or PMA (1 m), respectively, was applied to the cells for 1 h (Fig. 6 ). These data confirmed that the PKA and the PKC pathways are functional in these cells. Carbachol, palmitic acid, and oleic acid were also tested for their ability to modulate proglucagon mRNA expression in parallel to GLP-1 secretion, but none of them modified proglucagon mRNA after 18 h of incubation (data not shown).
Discussion
The evidence that glucose-dependent insulinotropic polypeptide is a potent stimulator of GLP-1 secretion in rodents but not in humans (8 -10, 24) underscores the importance of studying potential regulators of GLP-1 release in a relevant human cell model. We report here, for the first time, the use of the human NCI-H716 cell line derived from a differentiated colon adenocarcinoma to examine the regulation of GLP-1 secretion by various agents and their potential mechanisms of action.
A uniform population of differentiated NCI-H716 cells showed a high GLP-1 content (2.2 Ϯ 0.45 pmol/10 6 cells) and an increased secretory capacity, with a basal release of 4.2 Ϯ 0.9% of the total GLP-1 cell content during a 2-h incubation period. For comparison, the mouse enteroendocrine STC-1 cell line has been described to contain 1.2 Ϯ 0.2 pmol GLP-1/10 6 cells with a secretion rate of 1.4 Ϯ 0.3% during the same interval (7) . Contrary to the secretin tumor cell line STC-1 (25) and the mouse L cell line GLUTag (26), the NCI-H716 cell line was unable to express the cholecystokinin gene as tested by RT-PCR (data not shown). This discrepancy could be attributable to the colonic origin of the NCI-H716 cells, cholecystokinin being localized in endocrine cells of the duodenal and jejunal mucosa but not in the terminal ileum and colon (27) .
In agreement with studies of intestinal L cells of animal origin, the release of GLP-1 by NCI-H716 cells was increased by protein hydrolysates (20) . However, although exposure of the ileum to peptone stimulated GLP-1 secretion in the isolated vascularly perfused rat intestine (20, 28) , ileal perfusion of peptone had no effect or only weak effects on plasma GLP-1 in humans (29) .
Both palmitic acid and oleic acid stimulated GLP-1 secretion in NCI-H716 cells, whereas only unsaturated fatty acids were effective in the rat enteroendocrine cell line and in fetal rat intestinal cells (8, 30) . In healthy subjects, olive oil induced higher concentrations of GLP-1 and glucose-dependent in- sulinotropic polypeptide than butter (13) . Further work will be needed to assess the structure-activity relationship of fatty acids with regard to the stimulation of GLP-1 secretion in NCI-H716 cells.
Neural stimulation of GLP-1 also constitutes an important part in the control of GLP-1 secretion. In particular, cholinergic activation is considered an efficient signal in humans, because atropine has been shown to decrease GLP-1 release after an oral load (31) . In NCI-H716 cells, carbachol, a cholinergic agonist, elicited a small but significant increase in GLP-1 secretion. This effect is consistent with observations made in rodent cellular models (24, 32) . GRP is a neuropeptide expressed in the central nervous system and peripheral organs, which functions both as gut hormone and neuromediator. It stimulates GLP-1 release in humans, rats, and dogs and represents another important part of the vagal signal, apart from the adrenergic and cholinergic pathways (33) . Placement of fat into the duodenum of rats has been reported to induce the release of GLP-1 from the distal intestine through a GRP-dependent mechanism (34) . Furthermore, when applied at 0.1 m, GRP stimulated GLP-1 secretion in the isolated vascularly perfused rat ileum (27) . Here, 0.7 m GRP significantly enhanced GLP-1 secretion in NCI-H716 cells, although to a lesser extent than in an animal organ model (27) . The relatively high effective dose of GRP allowing stimulation of GLP-1 secretion in NCI-H716 cells could be attributable to the limited GRP receptor gene expression observed with RT-PCR in these cells compared with colon cancer CaCo-2 cells (data not shown). Interestingly, GRPenhanced GLP-1 secretion was correlated with an increase of cytosolic calcium levels in NCI-H716 cells. Similarly, Ca 2ϩ ionophore strongly stimulated GLP-1 secretion in these cells, as previously reported in fetal rat intestinal cell cultures (32) . The stimulation of the calcium signaling pathway by GRP has been described previously for the control of chromogranin A and neurotensin secretion in pancreatic cells transfected with a human GRP receptor (35) . In pancreatic and chromaffin cells, calcium entry through specific channels is responsible for the exocytosis of secretory granules (36, 37) . Therefore, it is tempting to speculate that a similar mechanism occurs in enteroendocrine cells. Nevertheless, further investigation is required to determine whether a calciumdependent exocytosis mechanism exists in these cells.
As previously described in rodent cellular models (8), the PKA-and PKC-dependent pathways were involved in the regulation of GLP-1 secretion in the human NCI-H716 cell line. However, proglucagon mRNA levels did not change in the NCI-H716 cells when incubated with PKA activators, which are known to up-regulate proglucagon gene expression in animal cell lines (8) . Genomic alterations arising in human colorectal tumor cell lines could be responsible for the lack of transcriptional response observed in the NCI-H716 cells. Nevertheless, the expression of c-fos, an early response gene, was up-regulated after NCI-H716 cells were incubated with forskolin or PMA, indicating effective PKA and PKC pathways (38) . Interestingly, promoter sequence differences between the rodent and human proglucagon gene, which could lead to potential differences in the mechanisms used for tissue-specific regulation, have been recently described (39) . Nucleotide changes were observed between the two promoters at the binding sites of transcription factors, including cAMP-responsive element-binding protein, pax6, HNF-3␣, and HNF-3␤ (39) . Modifications in the interaction of one or more of these factors with the human proximal promoter could explain the differences in proglucagon gene regulation observed between rodent and human cells. This hypothesis requires further investigation.
In conclusion, this study indicates that differentiated NCI-H716 cells, which express high levels of GLP-1, represent a useful cellular model for the study of the regulation of GLP-1 secretion in humans. With this model, we demonstrated that GRP stimulates GLP-1 secretion, probably through an increase of cytosolic calcium. Although the pathways regulating GLP-1 secretion in these human enteroendocrine cells appear to be similar to those previously described in rodent cells, the potential interspecies divergence in the regulation of proglucagon gene expression underscores the importance of further studying GLP-1 regulation in human models.
